EGFR and non-small cell lung carcinoma: In a single-center retrospective study evaluating NSCLC patients with EGFR-mutant (n = 22) or ALK-rearranged (n = 6) NSCLC treated with IO, objective response was observed in only one patient with EGFR mutation and ORR in patients with ALK-rearrangement was 0%, in contrast to 7 of 30 patients (23.3%) with EGFR wild type or ALK-negative/unknown (p = 0.053) [53].